3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
167
Leukemia
86
Precursor Cell Lymphoblastic Leukemia-Lymphoma
71
Lymphoma
51
Myelodysplastic Syndromes
38
Congenital Abnormalities
32
Burkitt Lymphoma
29
Lymphoma, Non-Hodgkin
27
Recurrence
26
Leukemia, Myelomonocytic, Acute
26
Leukemia, Monocytic, Acute
26
Lymphoma, Mantle-Cell
23
Leukemia, Erythroblastic, Acute
23
Leukemia, Megakaryoblastic, Acute
21
Hodgkin Disease
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
13
Myeloproliferative Disorders
12
Leukemia, Myelomonocytic, Chronic
11
Leukemia, Biphenotypic, Acute
11
Leukemia, Eosinophilic, Acute
9
Blast Crisis
9
Lymphoma, B-Cell
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Anemia, Refractory, with Excess of Blasts
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neoplasms
7
Multiple Myeloma
7
Leukemia, Basophilic, Acute
7
Leukemia, Lymphocytic, Chronic, B-Cell
6
Interventions
Brentuximab Vedotin
13
fludarabine
8
Cyclophosphamide
8
Rituximab
6
ruxolitinib
5
fludarabine phosphate
5
Melphalan
5
Lenalidomide
5
ponatinib
4
Dexamethasone
4
Busulfan
4
Bortezomib
4
nilotinib
3
Whole-Body Irradiation
3
Vincristine
3
Prednisone
3
Mycophenolic Acid
3
Imatinib Mesylate
3
Doxorubicin
3
Bendamustine Hydrochloride
3
Alemtuzumab
3
vosaroxin
2
pomalidomide
2
Tacrolimus
2
Sugars
2
Stem Cell Transplantation
2
Sirolimus
2
Ondansetron
2
Leukapheresis
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hematologic Diseases
×
Cytarabine
×
Clear all
NCT01191801
2018-08-22
VALOR
Sunesis Pharmaceuticals
Phase 3
Completed
711 enrolled
15 charts